TRACON Pharmaceuticals (NASDAQ:TCON) said it has appointed Dr Brenda Marczi as its senior vice president, Regulatory Affairs.
In her new role Dr Marczi brings more than three decades of regulatory affairs experience to TRACON. Previously Marczi served as vice president, regulatory affairs at Ferring Pharmaceuticals where she was responsible for all US regulatory activities, including the launch and commercialization activities for the breakthrough designation gene therapy product for non-muscle invasive bladder cancer.
She also held senior roles at Eagle Pharmaceuticals and Berlex - now Bayer AG - where she oversaw the filing of multiple successful new drug applications.
READ: TRACON Pharmaceuticals announces appointment of Ya Huang as executive director of Statistical Programming
“We are very pleased to welcome Brenda to the senior management team at TRACON,” Charles Theuer, president and CEO of TRACON said in a statement. “Her vast regulatory affairs experience working with the FDA will be instrumental to TRACON as we execute on our plan to complete the ENVASARC trial.”
As part of the appointment Marczi was issued an inducement award consisting of an option to purchase an aggregate of 60,000 shares of the TRACON’s common stock. The option has an exercise price per share equal to $4.90, which was the closing price of TRACON’s common stock on the Nasdaq Capital Market on the date the award was granted.
Commenting on her new position, Marczi said: “I am thrilled to join the impressive team at TRACON during such a pivotal time in the Company’s development of envafolimab. I look forward to helping the company achieve its goal of commercializing novel oncology therapies.”
Based in San Diego, TRACON develops targeted therapies for cancer utilizing a capital-efficient, CRO-independent, product development platform.
Currently, the company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase I development for the treatment of advanced solid tumors.
Contact the writer at georgia@proactiveinvestors.com
Follow her on Twitter @MissInformd